DIMENSION(R) RXL PSA FLEX(R) REAGENT CARTRIDGE

Prostate-specific Antigen (psa) For Management Of Prostate Cancers

FDA Premarket Approval P000021

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the dimension(r) rxl psa flex(r) reagent cartridge. The device is indicated for the following: the psa method for the dimension(r) clinical chemistry system with the heterogeneous immunoassay module is an in vitro diagnostic test intended to quantitatively measure prostate specific antigen (psa) in human serum: 1) as an aid in the detection of prostate cancer when used in conjunction with digital rectal exam (dre) in men aged 50 years or older. Prostate biopsy is required for the diagnosis of cancer. 2) as an aid in the management (monitoring) of prostate cancer patients.

DeviceDIMENSION(R) RXL PSA FLEX(R) REAGENT CARTRIDGE
Classification NameProstate-specific Antigen (psa) For Management Of Prostate Cancers
Generic NameProstate-specific Antigen (psa) For Management Of Prostate Cancers
ApplicantSIEMENS HEALTHCARE DIAGNOSTICS
Date Received2000-06-05
Decision Date2001-07-05
Notice Date2001-07-23
PMAP000021
SupplementS
Product CodeLTJ
Docket Number01M-0310
Advisory CommitteeImmunology
Expedited ReviewNo
Combination Product No
Applicant Address SIEMENS HEALTHCARE DIAGNOSTICS 500 Gbc Drive po Box 6101 newark, DE 19714-6101
Summary:Summary of Safety and Effectiveness
Labeling: Labeling
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P000021Original Filing
S044 2021-11-18 30-day Notice
S043 2020-09-14 30-day Notice
S042
S041 2019-06-19 30-day Notice
S040 2019-05-13 30-day Notice
S039 2018-09-28 Real-time Process
S038 2018-06-18 30-day Notice
S037 2018-04-17 30-day Notice
S036
S035 2017-11-20 30-day Notice
S034 2017-10-16 30-day Notice
S033 2017-09-25 Normal 180 Day Track No User Fee
S032 2017-06-20 30-day Notice
S031 2017-04-26 30-day Notice
S030 2017-02-17 30-day Notice
S029 2016-08-03 30-day Notice
S028 2015-12-07 Normal 180 Day Track
S027 2015-06-04 135 Review Track For 30-day Notice
S026 2014-08-27 30-day Notice
S025 2013-05-03 30-day Notice
S024 2012-10-31 30-day Notice
S023 2012-03-20 Real-time Process
S022 2012-03-08 30-day Notice
S021 2011-11-22 30-day Notice
S020 2011-06-30 Normal 180 Day Track
S019 2010-10-18 Real-time Process
S018 2010-08-19 Normal 180 Day Track
S017 2010-07-06 Real-time Process
S016 2010-03-25 30-day Notice
S015 2009-05-19 Normal 180 Day Track
S014 2009-04-06 Real-time Process
S013 2008-12-02 Normal 180 Day Track
S012 2008-03-03 Special (immediate Track)
S011 2008-02-26 30-day Notice
S010 2007-08-14 Real-time Process
S009 2006-12-06 30-day Notice
S008 2005-06-24 30-day Notice
S007
S006 2005-04-01 Special (immediate Track)
S005 2005-01-31 30-day Notice
S004 2004-11-15 Real-time Process
S003 2003-12-17 Real-time Process
S002 2002-03-26 Normal 180 Day Track
S001 2001-07-12 Real-time Process

NIH GUDID Devices

Device IDPMASupp
00842768013874 P000021 001
00842768016660 P000021 013

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.